Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353350 | 1.00 | KMT2A (0.48) | KMT2ACRHBPCRHR2MAPTRAB9A | |
| SCHEMBL19367477 | 0.82 | PIK3CA (0.60) | KMT2ACRHBPCRHR2MAPTRAB9A | |
| SCHEMBL305261 | 0.80 | PIK3CA (0.64) | RAB9APIK3CA | |
| SCHEMBL3276269 | 0.80 | PIK3CA (0.58) | KMT2ACRHBPCRHR2MAPTRAB9A | |
| SCHEMBL361909 | 0.78 | MLYCD (0.42) | KMT2AMAPTHTTSMN1; SMN2MEN1 | |
| SCHEMBL25062364 | 0.74 | GSK3B (0.51) | KMT2AMAPTRAB9AHTTATM | |
| SCHEMBL19367482 | 0.72 | HTT (0.49) | KMT2ACRHBPCRHR2MAPTRAB9A | |
| SCHEMBL2713615 | 0.72 | MLYCD (0.39) | KMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL13336854 | 0.72 | KMT2A (0.57) | KMT2ACRHBPCRHR2MAPTRAB9A | |
| SCHEMBL3927915 | 0.72 | KMO (0.62) | KMT2AMAPTRAB9AHTTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| EP-4137481-A1 | ARYL OR HETEROARYL DERIVATIVE | Teijin Pharma Limited (JP) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021210650-A1 | ARYL OR HETEROARYL DERIVATIVE | 帝人ファーマ株式会社 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | KMT2A 3894/4885CRHBP 4633/4885CRHR2 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.